Business Context and Reporting Period
Pacific Biosciences of California, Inc. filed this Form 8-K on April 26, 2017, to report financial results for the quarter ended March 31, 2017. The filing includes unaudited condensed consolidated financial statements and updated disclosures regarding legal proceedings and risk factors.
Key Financial Metrics
- Total Revenue: $24.9 million for Q1 2017, up 30% from $19.1 million in Q1 2016.
- Product and Service Revenue: $24.9 million, representing a 60% increase from $15.5 million in Q1 2016.
- Gross Profit: $8.9 million, resulting in a gross margin of 35.9%.
- Operating Expenses: $32.2 million, compared to $28.1 million in Q1 2016.
- Net Loss: $23.9 million, compared to a net loss of $19.4 million in Q1 2016.
- Liquidity: Cash, cash equivalents, and investments (excluding restricted cash) totaled $56.1 million as of March 31, 2017, down from $72.0 million at December 31, 2016.
- Stock-Based Compensation: $4.5 million included in operating expenses for Q1 2017.
Material Changes Versus Prior Period
- Revenue Composition: Q1 2016 included $3.6 million of contractual revenue, whereas Q1 2017 included no contractual revenue. This shift impacts year-over-year margin comparisons.
- Gross Margin Adjustment: The reported gross margin of 35.9% includes a $1.3 million charge to cost of revenue related to RS II instruments due to a change in estimated useful life. Excluding this charge, the adjusted gross margin would have been 41.0%.
- Expense Growth: Operating expenses increased by $4.1 million year-over-year, driven partly by higher stock-based compensation.
- Cash Position: The company's cash and investment balance decreased by $15.9 million during the quarter.
Guidance, Outlook, and Risks
The filing contains forward-looking statements based on management's current beliefs and assumptions. The company explicitly states that actual results could differ materially due to risks described in its most recent Form 10-K. No specific numerical guidance for future periods is provided in this text. The company has updated its Legal Proceedings and Risk Factors disclosures, which are incorporated by reference in Exhibit 99.2.
Investor Verification Checklist
- Verify the impact of the $1.3 million charge to cost of revenue on future quarters and the rationale for the change in estimated useful life of RS II instruments.
- Review the updated Legal Proceedings and Risk Factors in Exhibit 99.2 for new contingencies.
- Assess the sustainability of the 60% growth in product and service revenue absent the contractual revenue present in the prior year.
- Monitor the burn rate given the $15.9 million decrease in cash and investments during the quarter.
- Confirm the breakdown of operating expenses to understand drivers beyond stock-based compensation.